Number of the records: 1  

Novel monoclonal antibodies specific for CTLD-SSC and sialomucin domains of endosialin, a mural cell marker of tumor vasculature

  1. TitleNovel monoclonal antibodies specific for CTLD-SSC and sialomucin domains of endosialin, a mural cell marker of tumor vasculature
    Author Kontseková Soňa 1986 SAVVIR - Virologický ústav SAV
    Co-authors Ohraďanová Anna SAVVIR - Virologický ústav SAV    SCOPUS    ORCID

    Polčicová Katarína 1976 SAVVIR - Virologický ústav SAV

    Tuomaala P.

    Pastorek Jaromír 1957- SAVVIR - Virologický ústav SAV

    Pastoreková Silvia 1961 SAVVIR - Virologický ústav SAV    ORCID

    Parkkila S.

    Baráthová Monika 1976- SAVVIR - Virologický ústav SAV    ORCID

    Source document International Journal of Oncology. Vol. 41, no. 1 (2012), p. 1365-1372
    Languageeng - English
    Document kindrozpis článkov z periodík (rbx)
    CitationsRouleau, C (Rouleau, Cecile)[ 1 ] ; Gianolio, DA (Gianolio, Diego A.)[ 1 ] ; Smale, R (Smale, Robert)[ 1 ] ; Roth, SD (Roth, Stephanie D.)[ 1 ] ; Krumbholz, R (Krumbholz, Roy)[ 1 ] ; Harper, J (Harper, Jay)[ 1 ] ; Munroe, KJ (Munroe, Kenneth J.)[ 1 ] ; Green, TL (Green, Tessa L.)[ 1 ] ; Horten, BC (Horten, Bruce C.)[ 1 ] ; Schmid, SM (Schmid, Steven M.)[ 1 ] ; Teicher, BA Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies MOLECULAR CANCER THERAPEUTICS Volume: 14 Issue: 9 Pages: 2081-2089, 2015
    CategoryADCA - Scientific papers in foreign journals registered in Current Contents Connect with IF (impacted)
    Category of document (from 2022)V3 - Vedecký výstup publikačnej činnosti z časopisu
    Type of documentčlánok
    Year2012
    Registered inWOS
    Registered inSCOPUS
    Registered inCCC
    DOI 10.3892/ijo.2012.1566
    article

    article

    rokCCIFIF Q (best)JCR Av Jour IF PercSJRSJR Q (best)CiteScore
    A
    rok vydaniarok metrikyIFIF Q (best)SJRSJR Q (best)
    201220112.399Q31.238Q1
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.